... IRVINE Calif. Oct. 4 /- IDM Pharma Inc....A webcast of the presentation will be available live and following the...About IDM Pharma ...IDM Pharma is focused on the development of innovative cancer products...

IRVINE, Calif., Oct. 4 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI), a biotechnology company focused on the development of
innovative cancer therapies, announced today that Timothy P. Walbert,
president and chief executive officer, will present a corporate overview at
the BIO InvestorForum in San Francisco on Thursday, October 11, 2007 at 1
p.m. PDT at the Palace Hotel.

IDM Pharma is focused on the development of innovative cancer products
that either destroy cancer cells by activating the immune system or prevent
tumor recurrence by triggering a specific adaptive immune response. IDM
Pharma is dedicated to maximizing the full therapeutic and commercial
potential of each of its innovative products to address the needs of
patients and the physicians who treat these patients.

The presentation described in this press release will include
forward-looking statements that reflect management's current views of
future events including statements regarding the Company's plans to
collect, analyze and submit additional Phase 3 data in an amended NDA for
L-MTP-PE and to respond to other matters raised by ODAC and the FDA, the
Company's confidence that the proposed NDA amendment will provide
substantial evidence for the continued regulatory approval process, the
review of the submissions for marketing approval of L-MTP-PE by the FDA and
the EMEA, and the Company's goal of making L-MTP-PE available to patients
as quickly as possible. Actual results may differ materially from the
forward-looking statements due to a number of important factors, including,
but not limited to, the possibility that the Company may not be able to
collect, analyze and submit additional data in an amendment to the NDA for
L-MTP-PE by the first quarter of 2008, if at all, the possibility that such
data will not support the benefit of L-MTP-PE in the treatment of
non-metastatic osteosarcoma, will not allow a more robust analysis of
L-MTP-PE, will not continue to support its overall survival benefit in
osteosarcoma, and may not provide substantial evidence for the potential
regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review
of the submissions for marketing approval of L-MTP-PE, the ability of the
Company to respond to questions raised by the FDA and EMEA in a
satisfactory manner, the time needed to respond to any issues raised by the
FDA and EMEA with regard to regulatory submissions for L-MTP-PE, the
possibility that regulatory authorities may not consider preclinical and
early clinical development work conducted by Ciba-Geigy and efficacy data
from the Phase 3 trial conducted by Children's Oncology Group as adequate
for their assessment of L-MTP-PE, which may cause delays in review, may
result in the regulatory authorities requiring the Company to conduct
additional clinical trials, or may result in a determination by the
regulatory authorities that the data does not support marketing approval,
whether regulatory authorities will approve L-MTP-PE within the time frame
expected by the Company or at all, and whether the Company will be able to
manufacture and commercialize L-MTP-PE even if it is approved by regulatory
authorities. Other risks affecting the Company and its drug development
programs include whether the Company or any of its collaborators will be
able to develop pharmaceutical products using the technologies of the
Company, whether clinical trial results to date are predictive of results
of any future clinical trials, risks associated with completing clinical
trials of product candidates, risks involved in the regulatory approval for
the Company's product candidates, the possibility that clinical testing may
reveal undesirable and unintended side effects or other characteristics
that may prevent or limit the commercial use of proposed products; whether
the cash resources of the Company will be sufficient to fund operations as
planned, including any further clinical trials of any of the Company's
product candidates; whether any steps taken by the Company to contain costs
will in fact result in sufficient reduction in expenses; reliance on key
employees, especially senior management; the risk that the Company may not
secure or maintain relationships with collaborators, and the Company's
dependence on intellectual property. These factors are more fully discussed
in the Company's Quarterly Report on Form 10-Q filed with the SEC for the
quarter ended June 30, 2007 and other periodic reports filed with the SEC.
The Company expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.

(Date:8/15/2017)... ... 15, 2017 , ... Nanomedical Diagnostics , a cutting-edge ... the launch of the new NHS Agile biosensor chip . The new ... a wide range of molecules, including small and large molecules, peptides, proteins, and ...

(Date:8/15/2017)... ... August 15, 2017 , ... Coffea arabica ... biotic and abiotic factors. During this educational webinar, participants will learn about the ... as gain a better understanding of how genomics is important for coffee breeding ...

(Date:8/10/2017)... Philadelphia, PA (PRWEB) , ... August 09, 2017 ... ... back to the classroom next week-- as students. From August 14th through the ... Institute. The institute, which debuted in the summer of 2016, provides Philadelphia-based middle ...

(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...

(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...